Novo Nordisk
Published: 02/04/2026
Headquarters: Bagsværd, Denmark
Website: Visit Website
Therapeutic Areas
- Diabetes
- Immunology
- General Medicine
- Obesity and Weight Management
Pipeline Overview
Key pipeline highlights include:
- CagriSema — Novo Nordisk’s next-generation obesity therapy combining cagrilintide (amylin analog) and GLP-1 semaglutide, with Phase 3 REDEFINE-1 results showing weight loss of up to 22.7% of body weight over 68 weeks. The company aims to file in early 2026 for a potential approval.
- Wegovy Pill (oral semaglutide 25 mg) — The first and only once-daily oral GLP-1 medicine approved for chronic weight management, delivering 16.6% weight loss if all study participants adhered to treatment on par with injectable Wegovy (semaglutide 2.4 mg).
- Zenagamtide — A unimolecular, long-acting GLP-1 and amylin receptor agonist available in both subcutaneous and oral formulations. Phase 2 results showed HbA1c reductions of up to 1.8% subcutaneously, with 89% of participants reaching target levels below 7%. Phase 3 for weight management is underway in the first quarter of 2026.
- Ziltivekimab — A monoclonal antibody targeting IL-6 activity, being studied for cardiovascular disease with Phase 3 readouts expected in 2026–2027.
- Mim8 — A next-generation FVIIIa-mimetic bispecific antibody for hemophilia, with Phase 3 dosing initiated.
- Akero Therapeutics (EFX) — In October 2025, Novo Nordisk acquired Akero Therapeutics for $5.2 billion, a clinical-stage company focusing on the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Latest News
- Novo Nordisk Announces Positive Results for Higher-Dose Wegovy®, Showing Significant Weight Loss in Adults with Obesity
- Novo Nordisk Announces Significant Price Reduction on Wegovy & Ozempic
- Novo Nordisk FDA Warning Letter Analysis
- Novo Nordisk Launches Oral Wegovy®, Marked as First-Ever GLP-1 Weight Loss Pill Available in the U.S.
- Novo Nordisk Seeks EU Approval for Higher Dose of Wegovy®, Promising Greater Weight Loss
- Novo Nordisk Seeks FDA Approval for “Super-Charged” Wegovy Dose; Review Expedited Under New Priority Program
- Novo Nordisk Seeks FDA Approval for Powerful New Combination Obesity Drug, CagriSema, Following Strong Phase 3 Data
- Novo Nordisk Unveils Cardiovascular Data for Semaglutide at Major European Cardiology Congress
- Novo Nordisk and Hims & Hers Legal Agreement with Landmark GLP-1 Supply Deal
- EMA Gives Positive Opinion for Novo Nordisk’s Alhemo® to Treat Hemophilia A and B Without Inhibitors
- FDA Approves First-Ever Weight-Loss Pill: Novo Nordisk’s Wegovy Pill to Launch in January
- Legal Landmark: Novo Nordisk Wins Final Appeal to Protect GLP-1 Innovation in China
- EU Approves Higher-Dose Wegovy for Adults with Obesity, Showing Significant Weight Loss Results
- Novo Nordisk Unveils Promising Phase 3 Data for Cagrilintide, a Novel Amylin Analogue for Obesity, Advancing to New Clinical Program
- Novo Nordisk’s CagriSema for Obesity and Type 2 Diabetes Shows Superior Results in REDEFINE 2 Trial
- Novo Nordisk’s Ozempic® Gains EU Recommendation for Peripheral Arterial Disease (PAD)
- Novo Nordisk Unveils Groundbreaking Semaglutide & CagriSema Data, Reshaping Obesity & Diabetes Treatment
- Novo Nordisk’s UBT251 Triple Agonist Achieves Landmark 2.16% HbA1c Reduction in Type 2 Diabetes Phase 2 Trial
- Novo Nordisk’s Wegovy® (Semaglutide) Receives FDA Approval for MASH Treatment
- Novo Nordisk’s Amycretin Shows Significant Efficacy in Phase 2 Trial, Demonstrating Major Weight Loss and HbA1c Reduction in Type 2 Diabetes
- Novo Nordisk’s Semaglutide Fails to Slow Alzheimer’s Progression in Phase 3 Trials; Shares Slide
- Ozempic® Results from STRIDE Shown to Improve Walking Distance and Quality of Life in Adults With Type 2 Diabetes and Peripheral Artery Disease (PAD)
- Novo Nordisk OpenAI Partnership: A New Era for Drug Discovery
Discover More
